PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 905331

[Thrombophlebitis migrans].

J F Merlen
View original source ↗Export metadata ↓

Abstract

Semantically, the term is correct, because inflammatory involvement of the vein wall predominates over thrombosis, and the indication for anti-inflammatory drugs is absolute while that for anticoagulants is secondary. The nosological characteristics are its relapsing, migratory and primary nature. But, in fact, this is a "signal-symptom", whether involving normal or varicose veins, with nodular or stranded appearance, with patches of hypodermal inflammation or erysipeloid. The major problem is that of aetiology: infections, systemic disease, blood diseases, deep-seated neoplasia... not to mention the gouty diathesis, hiatus hernia, polycythaemia, Buerger's disease and Behçet's syndrome... The author emphasizes the value of capillaroscopy, biopsy of vein and digital pulp and the search for antivein antibodies. Therapy is discussed.

Explore related subjects

Anti-Inflammatory AgentsAnticoagulantsHumansPhlebitisRecurrenceThrombophlebitisThrombosisEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J F Merlen. [Thrombophlebitis migrans].. https://pubmed.ncbi.nlm.nih.gov/905331/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

A randomized comparison of dexamethasone 0.15 mg/kg versus 0.6 mg/kg for the treatment of moderate to severe croup.

BACKGROUND: Although previous studies have shown that dexamethasone is useful in croup, the optimal dosage has not been clarified yet. The aim of this study was to investigate the effectiveness of dexamethasone 0.15 mg/kg single dose compared with the recommended dose of 0.6 mg/kg for treatment of hospitalized children with moderate to severe croup. METHOD: Forty-one children aged 6 months to 5 years admitted from March 2001 to October 2003 at the pediatric ward of Hatyai Hospital with moderate to severe croup were recruited for the study. After random allocation, each child received a single intravenous injection of either dexamethasone 0.6 mg/kg (maximum dose 12 mg) or 0.15 mg/kg (maximum dose 3 mg). All children were given a single dose of epinephrine nebulization at the beginning of the study. The croup scores were measured at 0, 1, 2, 3, 4, 6, 8, 10 and 12 h after the dexamethasone injection. RESULTS: One hour following the injection, the mean croup scores were significantly reduced from baseline values in both groups (p<0.01). There was no difference in the mean croup scores between the two groups at any time. Median times to croup scores equal or less than two in both high- and low-dose groups were 8 and 7.9 h, respectively. No patient required intubation or was removed from the study because of a rising croup score after enrollment. There was no significant adverse reaction from dexamethasone treatment in either group. CONCLUSION: Dexamethasone 0.15 and 0.6 mg/kg are equally effective in the treatment of moderate to severe croup.

Anti-Inflammatory Agents↗